Stock Detail
NOVAVAX INC
Sector: Biotechnology
Latest Quote @ Wed May 5 04:46:48 (15 min delayed)
| $1.92 |
$2.48 |
$1.96 |
-0.02 |
-1.01% |
|
Last Day's Data
| $1.96 |
$2.02 |
$0.00 |
0.00% |
0.00 |
$1.98 |
| $1.99 |
$1.95 |
710,234.00 |
297.60M |
1.22M |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 2.05 |
2.01 |
1.98 |
1.94 |
1.91 |
Stock Profile
Novavax, Inc. engages in the research, development, and commercialization of products for women's health and infectious diseases. Its primary product candidate ESTRASORB, a topical emulsion for estrogen therapy, is used for the treatment of vasomotor symptoms associated with menopause. The company's other products comprise a line of prenatal multivitamin tablets, including Novanatal, NovaStart, and Nestabs for use before, during, and after pregnancy; Gynodiol, an oral estrogen replacement therapy; AVC Cream for the treatment of vaginal infection; and Analpram HC for relief of inflammation and pruritus associated with conditions, such as hemorrhoids and anal fissures. Novavax is also developing ANDROSORB, a topical lotion for testosterone replacement therapy in women; ANDRO-Ject, which delivers therapeutic levels of androgen using a subcutaneous testosterone delivery system; and delivery systems, and therapeutic and preventative vaccines for various markets. In addition, the company conducts research and development on preventative vaccines and proteins for infectious diseases and cancers; and tolerogens to prevent the initiation and progression of stroke, heart attack, and other inflammatory diseases. Novavax has collaborative agreements with the National Institutes of Health for the development of AIDS vaccine and an avian flu vaccine to prevent a pandemic outbreak; National Cancer Institute to develop anticancer vaccines for the treatment of melanoma; NIAID, Walter Reed Army Institute for Research, and GlaxoSmithKline Pharmaceuticals for the development of vaccines to prevent hepatitis caused by Hepatitis E virus; and with Wave Biotech LLC to develop pandemic influenza vaccine production technologies. The company sells its products to obstetricians, gynecologists, managed care organizations, wholesalers, and retail pharmacies through direct sales force and distributors in the United States. Novavax was formed in 1987 and is headquartered in Malvern, Pennsylvania.
